drugset / Trial / NCT07587125
Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis
Phase 1
Not yet recruiting
9 enrolled
Xijing Hospital
Hebei Senlang Biotechnology Inc., Ltd. · collab
NaSequentialOpen-labelTreatment
Summary
This study is a single-center, open-label, single-arm, exploratory clinical study to evaluate the safety, tolerability, and preliminary efficacy of S103（BCMA-CAR T ）cells in the treatment of progressive or refractory multiple sclerosis. The study is a dose escalation trial in adult progressive and refractory MS patients. A standard "3+3" design will be used to perform dose escalation to explore the safety profile and dose-limiting toxicities (DLTs). A total of 9 MS patients who meet the inclusion criteria are expected to be recruited.
Timeline
- Start
- 2026-05
- Primary completion
- 2027-11
- Completion
- 2029-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | S103 cells | Cell therapy | 500000 cells/kg | — |
| Subject | S103 cells | Cell therapy | 1e+06 cells/kg | — |
| Subject | S103 cells | Cell therapy | 2e+06 cells/kg | — |